Zimmer Biomet

Zimmer Biomet rose approximately 2% to $86.69, primarily driven by strong first-quarter results and positive guidance. The company reported Q1 2026 revenue of $2.087 billion, up 9.3% year-over-year, with earnings per share of $1.22, up 34% compared to the prior year, and net profit increasing 30.8%, exceeding market expectations. Management announced an increase to full-year EPS guidance alongside a stock buyback authorization, followed by a quarterly dividend of $0.24 per share, signaling confidence in operational momentum. However, analyst sentiment remains mixed: Citigroup recently lowered its price expectations, and some institutional investors have trimmed positions, reflecting caution about future growth prospects. From a valuation perspective, the stock is currently trading approximately 20% below its 52-week high of $108.29 and down 3.7% year-to-date, though it remains above its 60-day moving average of $87.99, suggesting relative technical stability. Wall Street's 12-month price target of $96.45 implies 13% upside potential.